CRBU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Caribou Biosciences Inc (CRBU) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock is trading at a low price of $1.96, with strong potential upside based on analyst price targets, hedge fund buying activity, and promising developments in its CAR-T cell therapy pipeline. Despite short-term volatility and negative earnings, the long-term growth prospects and positive sentiment from analysts make it a suitable investment for a patient, long-term investor.
The MACD histogram is positive at 0.0554, indicating bullish momentum, but it is contracting. RSI is at 66.313, which is neutral and not overbought or oversold. Moving averages are converging, suggesting no strong trend. Key support is at 1.538, and resistance is at 2.111, with the stock trading near resistance levels.
Analysts have given a 'Buy' rating with a price target as high as $13, indicating significant upside potential.
Hedge funds are aggressively buying, with a 1731.04% increase in buying activity last quarter.
Promising pipeline of CAR-T cell therapies with potential peak sales in the hundreds of millions by 2040.
The company is currently unprofitable, with a net income loss of -$27.55M in Q3
EPS dropped by 21.05% YoY, reflecting continued financial challenges.
The stock is highly volatile, which may not suit risk-averse investors.
In Q3 2025, revenue increased by 8.60% YoY to $2.198M, but net income dropped by -20.57% YoY to -$27.55M. EPS declined by -21.05% YoY to -$0.3. Gross margin remained stable at 100%. While revenue growth is positive, the company is still operating at a loss.
Clear Street initiated a 'Buy' rating with a $13 price target, citing the potential of Caribou's CAR-T therapies. BofA maintained a 'Buy' rating but lowered its price target from $8 to $6, reflecting cautious optimism. Analysts highlight the company's promising pipeline but acknowledge risks due to the early stage of development and financial losses.
